arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

MBX Biosciences, Inc.

MBX Health Care Biotechnology: Pharmaceutical Preparations
$61.72
Today
as of Sep 4, 16:51 ET
Last 30 days +2.76% Jul 28 → Sep 04
$59.21 $62.29 $65.38 $68.47 $71.55 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$61.00
High
$62.73
Low
$60.59
Volume
$271,773
Avg Vol
$862,115
Mkt Cap
$3.2B
P/E (TTM)
—
Beta
—
52w High
$72.64
52w Low
$9.63
Div Yield
—
Shares Out
$48M

Recent Press Releases & News last 60 days · 6 items

Aug 27 · 12:00 PR GlobeNewswire
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
Aug 10 · 10:11 MT Newswires
Truist Adjusts Price Target on MBX Biosciences to $88 From $70, Maintains Buy Rating
Aug 6 · 14:40 MT Newswires
MBX Biosciences Shares Lower After Q2 Loss Widens
▸ Show all 6 press releases & news Free account →

Overview

52-week range
$9.63
$73
83% of range
Avg surprise (last 3)
+18.3%
Avg reaction (last 2)
+4.2%
100% positive
Latest IV / EM
74%
EM ±11.5% · $60 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-12.62$-9.59$-6.56$-3.54$-0.51 Actual $-9.40Actual $-10.26Actual $-12.62Actual $-2.78Actual $-0.71Est $-0.81Actual $-0.58Est $-0.77Actual $-0.63Actual $-0.51Est $-0.62Actual $-0.78 SepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-37M$-33M$-28M$-24M$-19M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.78 — — — — financials
Thu May 7, 2026Mar/2026 $-0.51 $-0.62 +17.7% +28.2% +8.1% earnings
Tue Sep 30, 2025Sep 2025 $-0.63 — — — — financials
Thu Aug 7, 2025Jun/2025 $-0.58 $-0.77 +24.7% — — earnings
Mon May 12, 2025Mar/2025 $-0.71 $-0.81 +12.3% — +0.3% earnings
Mon Sep 30, 2024Sep 2024 $-2.78 — — — — financials
Sun Jun 30, 2024Jun 2024 $-12.62 — — — — financials
Sun Mar 31, 2024Mar 2024 $-10.26 — — — — financials
Sat Sep 30, 2023Sep 2023 $-9.40 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-41M$-27M—$-24M$-22M$-27M—$-20M
Net income$-37M$-24M—$-22M$-19M$-24M—$-18M
EPS (diluted)$-0.78$-0.50—$-0.63$-0.58$-0.71—$-2.78

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$54M$45M$75M$223M$40M$30M$49M$133M
Inventory————————
Total current assets$428M$449M$382M$398M$229M$244M$267M$281M
Total assets$436M$453M$385M$400M$232M$246M$269M$282M
Long-term debt————————
Total liabilities$26M$15M$16M$13M$12M$11M$11M$11M
Total equity$410M$438M$369M$388M$219M$235M$257M$271M

Implied volatility — last 90 days

65%106%147%189%230% Jun 07 — IV 153% · EM ±21.1%Jun 08 — IV 167% · EM ±22.1%Jun 09 — IV 191% · EM ±23.9%Jun 10 — IV 180% · EM ±21.2%Jun 11 — IV 172% · EM ±19.1%Jun 12 — IV 147% · EM ±15.1%Jun 15 — IV 152% · EM ±11.0%Jun 16 — IV 203% · EM ±12.0%Jun 17 — IV 230% · EM ±9.6%Jun 19 — IV 108% · EM ±23.9%Jun 22 — IV 115% · EM ±24.0%Jun 23 — IV 111% · EM ±22.8%Jun 24 — IV 109% · EM ±21.8%Jun 25 — IV 110% · EM ±21.5%Jun 26 — IV 104% · EM ±20.0%Jun 29 — IV 120% · EM ±21.2%Jun 30 — IV 118% · EM ±20.4%Jul 01 — IV 111% · EM ±18.6%Jul 02 — IV 120% · EM ±19.4%Jul 03 — IV 124% · EM ±19.4%Jul 06 — IV 138% · EM ±19.2%Jul 07 — IV 148% · EM ±19.5%Jul 08 — IV 106% · EM ±13.3%Jul 09 — IV 98% · EM ±11.6%Jul 10 — IV 83% · EM ±9.2%Jul 13 — IV 120% · EM ±10.0%Jul 14 — IV 120% · EM ±8.7%Jul 15 — IV 148% · EM ±8.7%Jul 16 — IV 222% · EM ±9.3%Jul 20 — IV 92% · EM ±21.8%Jul 21 — IV 91% · EM ±21.1%Jul 22 — IV 96% · EM ±21.9%Jul 23 — IV 95% · EM ±21.4%Jul 24 — IV 84% · EM ±18.7%Jul 27 — IV 92% · EM ±19.2%Jul 28 — IV 91% · EM ±18.6%Jul 29 — IV 97% · EM ±19.4%Jul 30 — IV 101% · EM ±19.7%Jul 31 — IV 95% · EM ±18.2%Aug 03 — IV 99% · EM ±17.5%Aug 04 — IV 89% · EM ±15.3%Aug 05 — IV 87% · EM ±14.5%Aug 06 — IV 87% · EM ±14.1%Aug 07 — IV 97% · EM ±15.2%Aug 10 — IV 95% · EM ±13.1%Aug 11 — IV 83% · EM ±10.9%Aug 12 — IV 83% · EM ±10.4%Aug 13 — IV 89% · EM ±10.5%Aug 14 — IV 99% · EM ±10.9%Aug 17 — IV 110% · EM ±9.2%Aug 18 — IV 99% · EM ±7.1%Aug 19 — IV 173% · EM ±10.2%Aug 20 — IV 208% · EM ±8.7%Aug 24 — IV 72% · EM ±15.1%Aug 25 — IV 69% · EM ±14.1%Aug 26 — IV 72% · EM ±14.5%Aug 27 — IV 65% · EM ±12.8%Aug 28 — IV 87% · EM ±16.6%Aug 31 — IV 68% · EM ±12.1%Sep 01 — IV 71% · EM ±12.3%Sep 02 — IV 75% · EM ±12.5%Sep 03 — IV 67% · EM ±10.9%Sep 04 — IV 74% · EM ±11.5%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in